GlaxoSmithKline, Vir increases supply of COVID-19 antibody therapy to Canada to 20,000 doses

glaxosmithkline,-vir-increases-supply-of-covid-19-antibody-therapy-to-canada-to-20,000-doses

GlaxoSmithKline PLC GSK, -0.53% announced Thursday an agreement to supply the Government of Canada with 20,000 doses of Sotrovimab, the COVID-19 monoclonal antibody therapy the company developed with Vir Biotechnology Inc. VIR, . The agreement follows Canada’s initial order of 10,000 doses of Sotrovimab announced in October, which included options for additional purchases. Sotrovimab was authorized for injection by Health Canada in July 2021 to treat mild to moderate COVID-19 in adults and adolescents 12 years old and older who are at high risk for hospitalization and death. Glaxo’s stock slipped 0.1% in afternoon trading and Vir shares eased 0.1%, while the S&P 500 SPX, -0.10% gained 0.1%.

Source: Marketwatch

Related Posts